Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the safety and outcomes associated between the two treatment modalities

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Vancomycin

Criteria

Inclusion Criteria:

• Adult patients at least 18 years of age

• Receiving Wake Forest Baptist Health OPAT services

• Will receive vancomycin therapy from Wake Forest Baptist Health Specialty Home Infusion Pharmacy

• Planned therapy with vancomycin in the outpatient setting for at least 2 weeks in duration

• Prescribed vancomycin with a frequency of either every 12 hours or every 8 hours dosing at the time of enrollment

Exclusion Criteria:

• Presence of diseases or conditions known to affect the pharmacokinetics of vancomycin:

Pregnancy/Ascites/Burn injury/Cystic fibrosis /Weight greater-than or equal-to 150 kg

• Pre-existing leukopenia:

WBC < 4,000 x 103 cells/µL